Affiliation:
1. Department of Dermatology, CHU Nice Université Côte d'Azur Nice France
2. Department of Clinical Research, Cimiez Hospital, CHU Nice Université Côte d'Azur Nice France
3. Pharmacy Department, CHU Nice Université Côte d'Azur Nice France
4. INSERM U1065, Centre Méditerranéen de Médecine Moléculaire Université Côte d'Azur Nice France
Abstract
AbstractBackgroundKligman's trio (KT), combining hydroquinone, retinoic acid and corticosteroid, is considered as the gold standard treatment of melasma. Its efficacy has never been matched before, but it is tempered by frequent adverse effects.ObjectiveTo assess the efficacy and tolerance of a New Trio (NT) combination with isobutylamido‐thiazolyl‐resorcinol, retinoic acid and cortosteroid compared to KT.MethodsWe conducted a 24‐week monocentric trial, randomized, double‐blind, controlled versus KT, with 40 melasma patients. NT and KT were applied for 12 weeks and associated with the same sunscreen applied for 24 weeks. The primary endpoint was the modified Melasma Area Severity Index (mMASI) at 12 weeks. Patient quality of life was investigated using MelasQoL.ResultsAfter 12 weeks, KT and NT groups both demonstrated a significant improvement in mMASI, respectively −2.84 (SE 0.69, p < 0.0002) and −4.33 (SE 0.71, p < 0.0001). The mean difference between the two groups was −1.49 (IC 95% −3.52 to 0.54, p = 0.14). MelasQoL improvement was −6.66 (SE 3.29, p = 0.0515) with KT and −12.57 (SE 3.29, p = 0.0006) with NT.ConclusionThe NT combination appears to be an effective treatment option for treating melasma and could be considered as a well‐tolerated alternative to KT.
Subject
Infectious Diseases,Dermatology
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献